Return to homepagePandemic Pact

Interferon-modulated vaccines against HIV

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3DP2DA051912-01S2

Grant search

Key facts

  • Disease

    N/A

  • Start & end year

    2020
    2024

  • Known Financial Commitments (USD)

    $81,547

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    ASST PROFESSOR Pablo Penaloza

  • Research Location

    United States of America

  • Lead Research Institution

    NORTHWESTERN UNIVERSITY AT CHICAGO

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Disabled persons

  • Occupations of Interest

    Unspecified

Abstract

Project Summary The main goal of the parent grant is to develop interferon-modulated vaccines against HIV. The proposed research will follow up on the same unifying concept of our parent DP2 grant, but in addition, it will consider the effect of boosting with a heterologous vaccine. Bakare has observed that boosting with a heterologous vaccine regimen enhances the efficacy of vaccines (manuscript in preparation). The preliminary data shown below is with SARS-CoV-2 vaccines, but it demonstrates a potentially novel and universal strategy to improve viral vaccines against HIV and other infectious agents that affect PWID. Improving vaccine efficacy is also critical to improve the lives of PWID.